RESUMO
Interleukin (IL)-10 plays crucial regulatory roles in immune responses by inhibiting the secretion of several cytokines (IL-2, IL-12, interferon-gamma (IFN-gamma)) and lymphocyte proliferation. Iron deficiency, a public health problem for children, alters these immune responses. To determine whether these changes are related to altered IL-10 secretion, we measured IL-10 in 24 and 48 h supernatant of spleen cell cultures from iron deficient (ID), control (C), pairfed (PF), and ID mice fed the control diet (iron repletion) for 3 (R3) and 14 (R14) days (d, n = 12/group). Mean levels of hemoglobin, hematocrit, and liver iron stores varied as follows: C approximately equal PF approximately equal R14 > R3 > ID (P < 0.01). Mean baseline IL-10 levels of ID mice tended to be higher than those of other groups (P > 0.05, ANOVA). Mean IL-10 levels secreted by concanavalin A (Con A) and antibody raised against cluster of differentiation molecule 3 (anti-CD3)-treated cells (+/-background) were lower in ID than in C (48 h) and iron replete mice (P < 0.05). Underfeeding also reduced IL-10 secretion by anti-CD3-treated cells (48 h, P < 0.05). Lymphocyte proliferative responses to anti-CD3 +/- anti-CD28 antibodies were lower in ID than in C and PF mice, and they were corrected by iron repletion (P < 0.05). IL-10 levels negatively correlated with indicators of iron status (r Assuntos
Concanavalina A/farmacologia
, Interleucina-10/metabolismo
, Deficiências de Ferro
, Mitógenos/farmacologia
, Baço/metabolismo
, Animais
, Antígenos CD28/imunologia
, Complexo CD3/imunologia
, Divisão Celular/imunologia
, Células Cultivadas
, Feminino
, Hematócrito
, Hemoglobinas/metabolismo
, Imunoglobulina G/farmacologia
, Fígado/imunologia
, Fígado/metabolismo
, Ativação Linfocitária
, Camundongos
, Camundongos Endogâmicos C57BL
, Baço/citologia
RESUMO
Infectious complications are not uncommon in children undergoing treatment for cancer. Abdominal pain, especially right lower quadrant pain secondary to appendiceal and cecal inflammation, is a major concern in immunocompromised hosts and a potential source of sepsis. The authors report the case of a child who developed acute perforative appendicitis requiring appendectomy while on preoperative chemotherapy for Wilms tumor, stage IV, favorable histology. Problems related to diagnosis and management of acute abdominal pain and infection in an immunocompromised child with an abdominal mass are discussed along with a review of the literature.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Apendicite/complicações , Perfuração Intestinal/etiologia , Neoplasias Renais/complicações , Terapia Neoadjuvante , Tumor de Wilms/complicações , Dor Abdominal/etiologia , Doença Aguda , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Apendicite/diagnóstico , Apendicite/tratamento farmacológico , Apendicite/cirurgia , Ceftazidima/uso terapêutico , Criança , Terapia Combinada , Dactinomicina/administração & dosagem , Doxorrubicina/administração & dosagem , Quimioterapia Combinada/uso terapêutico , Emergências , Gentamicinas/uso terapêutico , Humanos , Hospedeiro Imunocomprometido , Perfuração Intestinal/diagnóstico , Neoplasias Renais/tratamento farmacológico , Neoplasias Renais/cirurgia , Masculino , Metronidazol/uso terapêutico , Nefrectomia , Ruptura Espontânea , Vincristina/administração & dosagem , Tumor de Wilms/tratamento farmacológico , Tumor de Wilms/cirurgiaRESUMO
Acute lymphocytic leukemia developed within 3 weeks after a fulminant case of varicella complicated by pneumococcal sepsis and severe bone marrow suppression in a child treated with filgrastim (human granulocyte colony-stimulating factor).
Assuntos
Varicela/complicações , Neutropenia/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras/virologia , Varicela/tratamento farmacológico , Feminino , Filgrastim , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Humanos , Imunofenotipagem , Lactente , Neutropenia/tratamento farmacológico , Neutropenia/virologia , Pancitopenia/complicações , Pancitopenia/tratamento farmacológico , Pancitopenia/virologia , Pneumonia Pneumocócica/complicações , Pneumonia Pneumocócica/tratamento farmacológico , Pneumonia Pneumocócica/virologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Proteínas Recombinantes , Sepse/complicações , Sepse/tratamento farmacológico , Sepse/virologiaAssuntos
Transfusão de Sangue/normas , Transfusão de Componentes Sanguíneos/normas , Transfusão de Componentes Sanguíneos/tendências , Transfusão de Sangue/tendências , Criança , Pré-Escolar , Feminino , Humanos , Índia , Lactente , Recém-Nascido , Masculino , Pediatria/métodos , Medição de Risco , Fatores de Risco , Sensibilidade e EspecificidadeRESUMO
A 12-year-old African American male with homozygous sickle cell disease (SCD) was admitted with insidious onset of periorbital and scrotal edema. The initial evaluation failed to reveal any underlying monoclonal gammopathy, or cryoglobulinemia, or other systemic causes for the renal disease. A percutaneous renal biopsy was consistent with immunotactoid glomerulopathy (ITG), which is rare in children and is characterized histologically by fibrillar deposits in the glomeruli. Children can present with symptoms of nephrotic syndrome and progress to end stage renal disease. Our patient was treated with an ACE inhibitor and is currently free of edema and with normal renal function on follow-up at 1 year. Immunotactoid glomerulopathy should be considered in the differential diagnosis of nephrotic syndrome in children with sickle cell disease. Renal biopsy is indicated in children with sickle cell disease and nephrotic syndrome and ITG should be considered as potential cause. Although there is no effective treatment for this condition, ACE inhibitors can decrease the protein-uria and possibly delay the progression to end stage renal disease. The side effects related to the use of ACE inhibitors should be monitored. These include renal impairment, hyperkalemia, anemia, neutropenia, and angioedema. Since we have a short follow-up in our patient, the role and safety of ACE inhibitors in the management of ITG need further evaluation.
Assuntos
Anemia Falciforme/complicações , Nefropatias/complicações , Nefropatias/imunologia , Glomérulos Renais , Criança , Diagnóstico Diferencial , Humanos , Nefropatias/patologia , Glomérulos Renais/patologia , Masculino , Síndrome Nefrótica/etiologiaRESUMO
We determined whether there is an association between tumor necrosis factor-alpha (TNF-alpha), undernutrition [prealbumin (PA) <160 mg/L, retinol binding protein (RBP) <30 mg/L], disease stage, outcome (death or survival), and race in children with leukemia. TNF-alpha, PA, and RBP were measured in 52 patients (0.8 to 17 years old): 18 African Americans, 34 whites; 27 newly diagnosed (ND), and 25 in clinical remission (CR). Mean levels of TNF-alpha were higher in patients than in 46 healthy children (p < 0.05), but were not different between ND and CR groups. Mean acute phase proteins (APP) were different among groups: ND > CR > controls (p < 0.05). Mean levels of PA and RBP were lower in patients than in controls (p < 0.051, and tended to be higher in CR than in ND patients. African-American patients had lower concentrations of TNF-alpha, PA, and RBP but higher APP than white patients (p < 0.05). CR patients and African-American patients who died tended to have higher levels of TNF-alpha and APP, but lower PA and RBP than those who survived. A higher percentage of ND African Americans (45%) than of ND whites (13%) died. Results suggest that undernutrition and inflammation in CR patients and African Americans were associated with poor survival, and that ND African Americans have a poorer outcome than whites independently of TNF-alpha levels.
Assuntos
Linfoma de Burkitt/sangue , Leucemia Mielomonocítica Aguda/sangue , Pré-Albumina/metabolismo , Proteínas de Ligação ao Retinol/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Proteínas de Fase Aguda/metabolismo , Adolescente , Negro ou Afro-Americano/estatística & dados numéricos , Análise de Variância , Linfoma de Burkitt/etnologia , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Leucemia Mielomonocítica Aguda/etnologia , Masculino , Estado Nutricional , Radioimunoensaio , Análise de Sobrevida , População Branca/estatística & dados numéricosRESUMO
Epstein-Barr virus-related lymphoproliferative disease (EBV-LPD) is a serious and often fatal complication of a variety of immune-suppressed conditions. A 6-year-old boy undergoing chemotherapy for standard-risk acute lymphocytic leukemia experienced separate episodes of EBV-LPD in different organ systems. The patient experienced three separate episodes of EBV-LPD in the cervical lymph node, the central nervous system (CNS), and the liver occurring, respectively, in January 1992, February 1992, and November 1993 after the completion of chemotherapy in May 1993. The EBV presence was confirmed by in situ hybridization in the biopsy samples from each lesion. Several different treatment modalities, including acyclovir, intravenous gamma globulin, and surgery were used to combat the EBV-LPD. The patient has recovered completely, with normal CNS and liver function, and for the past 6 years has experienced leukemia remission while not receiving chemotherapy. Careful monitoring of patients and the use of new immune therapies offer the highest chance for successful outcomes in such patients.
Assuntos
Doenças do Sistema Nervoso Central/virologia , Infecções por Vírus Epstein-Barr/complicações , Herpesvirus Humano 4 , Leucemia-Linfoma Linfoblástico de Células Precursoras/virologia , Doenças do Sistema Nervoso Central/complicações , Criança , Humanos , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Tomografia Computadorizada por Raios XAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Fibrossarcoma/tratamento farmacológico , Carboplatina/administração & dosagem , Ciclofosfamida/administração & dosagem , Dactinomicina/administração & dosagem , Intervalo Livre de Doença , Doxorrubicina/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Fibrossarcoma/cirurgia , Humanos , Ifosfamida/administração & dosagem , Lactente , Recém-Nascido , Masculino , Mesna/administração & dosagem , Neoplasias de Tecidos Moles/tratamento farmacológico , Neoplasias de Tecidos Moles/cirurgia , Vincristina/administração & dosagemRESUMO
We conducted this study to determine whether children with cerebral malaria are less likely to have tissue iron deficiency than those with non-cerebral malaria. Iron status was assessed by soluble transferrin receptor (sTfR), serum ferritin, and haemoglobin in 44 Zaïrian children: 15 with cerebral malaria, 14 with non-cerebral malaria, and 15 without malaria (age range 0.5-16 years). Although there was no significant difference in the mean concentrations of sTfR, serum ferritin, or haemoglobin between either group of patients, a higher percentage of children with cerebral malaria (27 per cent) than those with non-cerebral malaria (14 per cent) or controls (7%) had sTfR levels above 7.3 mg/l (suggestive of tissue iron deficiency). A higher percentage of children with cerebral malaria (40 per cent) than with non-cerebral malaria (29 per cent) or controls (20 per cent) also had either serum ferritin < 100 micrograms/l and inflammation or sTfR > 7.3 mg/l or both. The data suggest that children with cerebral malaria are as likely to have tissue iron deficiency as those with non-cerebral malaria.
Assuntos
Anemia Ferropriva/sangue , Anemia Ferropriva/etiologia , Malária Cerebral/complicações , Malária Falciparum/complicações , Receptores da Transferrina/sangue , Adolescente , Estudos de Casos e Controles , Criança , Pré-Escolar , Estudos Transversais , Feminino , Ferritinas/sangue , Hemoglobinas/análise , Humanos , Lactente , Inflamação , Malária Cerebral/imunologia , Malária Falciparum/imunologia , MasculinoRESUMO
A discussion of a 5-year-old child with congenital hemolytic anemia and severe hypotonia caused by triosephosphate (TPI) deficiency is presented. The complexities in the diagnosis and management of this condition is discussed and the relevant literature is reviewed.
Assuntos
Anemia Hemolítica Congênita/genética , Hipotensão/fisiopatologia , Triose-Fosfato Isomerase/genética , Anemia Hemolítica Congênita/metabolismo , Anemia Hemolítica Congênita/fisiopatologia , Pré-Escolar , Feminino , Humanos , Hipotensão/genética , Hipotensão/metabolismo , Mutação Puntual , Triose-Fosfato Isomerase/deficiênciaRESUMO
PURPOSE: To report the occurrence of focal segmental glomerulosclerosis (FSGS) in children with acute lymphocytic leukemia (ALL), discuss pathogenesis and problems in management. PATIENTS AND METHODS: Progressive renal dysfunction developed in two adolescent black girls with high-risk ALL who underwent renal biopsies that were consistent with FSGS. In both patients, no known etiologic factors, such as systemic lupus erythematosus, poststreptococcal glomerulonephritis, sickle cell anemia, or acquired immunodeficiency syndrome, were evident. FSGS induced by Adriamycin (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats. The patients had received anthracyclines and methotrexate, a known nephrotoxic chemotherapeutic agent. RESULTS: One patient progressed to chronic renal failure and required prolonged dialysis followed by renal transplantation, though the leukemia remained in remission. The other patient is also in remission and on maintenance treatment for leukemia. She has persistent proteinuria and is currently undergoing a trial of high-dose steroid therapy. CONCLUSION: The combination of FSGS with leukemia poses a management challenge to the clinician in terms of further treatment with potentially nephrotoxic drugs, complications of nephrotic syndrome (including infections), and timing of renal transplantation. Future studies should address whether FSGS represents a glomerular response to anthracycline-induced injury in susceptible black persons.
Assuntos
Glomerulosclerose Segmentar e Focal/etiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Adolescente , Animais , Antraciclinas/efeitos adversos , Antraciclinas/uso terapêutico , Antimetabólitos Antineoplásicos/efeitos adversos , Antimetabólitos Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Criança , Feminino , Glomerulosclerose Segmentar e Focal/fisiopatologia , Glomerulosclerose Segmentar e Focal/terapia , Humanos , Metotrexato/efeitos adversos , Metotrexato/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , RatosRESUMO
PURPOSE: To report the efficacy of hydroxyurea (HU) in a patient with sickle cell anemia (SCA) associated with systemic lupus erythematosus (SLE). PATIENTS AND METHODS: An unusual association of SCA with SLE occurred in a 14-year-old black girl. Her medical history was significant for repeated vasoocclusive crises requiring repeated hospitalizations and transfusions, acute chest syndrome, hyperhemolytic crises, multiple transfusions resulting in iron overload, gall stones, avascular necrosis, and significant psychosocial problems. Her lupus activity was controlled with oral prednisone and hydroxychloroquine. Treatment with oral HU was instituted at an initial dose of 20 mg/kg with gradual increment to a maximum of 25 mg/kg daily. RESULTS: A dramatic clinical improvement was noted with HU therapy with no episode of pain crisis or hospitalization for 5 months. There was an increase in fetal hemoglobin (HbF) to 20.9% and mean corpuscular volume to 114.5 fl, but her Hb level remained steady at 7.5 g/dl. No toxicity was noted with HU therapy. In addition, a significant change was also observed in her school performance, social activities, and general quality of life. CONCLUSIONS: HU therapy may be beneficial and safe and should be considered for other patients who have SCA with SLE.
Assuntos
Anemia Falciforme/complicações , Antidrepanocíticos/uso terapêutico , Hidroxiureia/uso terapêutico , Lúpus Eritematoso Sistêmico/complicações , Adolescente , Anemia Falciforme/sangue , Anemia Falciforme/tratamento farmacológico , Anemia Falciforme/psicologia , Antidrepanocíticos/farmacologia , Avaliação de Medicamentos , Índices de Eritrócitos , Feminino , Hemoglobina Fetal/análise , Hemoglobina Fetal/biossíntese , Hemoglobina Fetal/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Hidroxicloroquina/uso terapêutico , Hidroxiureia/farmacologia , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Lúpus Eritematoso Sistêmico/psicologia , Prednisona/uso terapêutico , Qualidade de VidaRESUMO
Iron deficiency impairs lymphocyte proliferation in humans and laboratory animals by unknown mechanisms. In this study, we investigated whether this alteration can be attributed in part to impaired hydrolysis of cell membrane phosphatidyl inositol-4, 5-bisphosphate (PIP2), a required early event of T-lymphocyte activation. The study involved 46 iron-deficient (ID), 26 control (C) and 23 pair-fed (PF) mice, and ID mice that were repleted for 3 (n = 16), 7 (n = 17) or 14 d (n = 18). Mice were killed after 40-63 d (mean, 48 d) of consuming the test diet (0.09 mmol/kg iron) or the control diet (0.9 mmol/kg). The mean (+/-SEM) hemoglobin concentrations were 57 +/- 16.7, 176 +/- 2.6 and 181 +/- 9.7 g/L for ID, C and PF groups, respectively. After splenic lymphocytes were labeled in vitro with 3H-myoinositol for 3 h, PIP2 hydrolysis was estimated by measuring the radioactivity recovered as a mixture of inositol mono-, di- and triphosphate (IP) from concanavalin A (0, 1, 2.5, 5 and 10 mg/L) activated cells. Although cells from ID mice and those from mice repleted for 3 d incorporated slightly more radioactivity in cellular phospholipids than did cells from C or PF mice, less (P < 0.005) was recovered as IP than in controls, suggesting impaired conversion of the precursor to PIP2. At almost all incubation periods (10-120 min) and mitogen concentrations, the rate of PIP2 hydrolysis expressed as the ratio of radioactivity obtained in Con A-treated to untreated cells was significantly (P < 0.05) reduced in cells from ID mice compared with those obtained from C and PF mice. For cells that were activated for 60 min or less, iron repletion for 14 d significantly (P < 0.05) improved the rate of PIP2 hydrolysis. PIP2 hydrolysis positively and significantly (P < 0.05) correlated (r = 0.27-0.56) with indicators of iron status. Mitogenic response was also significantly (P < 0.05) reduced in ID but not PF mice, and it was corrected by iron repletion for 3, 7 or 14 d. Lymphocyte proliferation positively (r = 0.27-0.37, P < 0.01) correlated with indices of iron status and IP ratios. The data suggest that reduced PIP2 hydrolysis contributes to impaired blastogenesis in iron deficiency.
Assuntos
Membrana Celular/metabolismo , Deficiências de Ferro , Ativação Linfocitária , Linfócitos/ultraestrutura , Fosfatidilinositol 4,5-Difosfato/metabolismo , Baço/citologia , Animais , Concanavalina A/farmacologia , Suplementos Nutricionais , Feminino , Hidrólise , Inositol/metabolismo , Ferro/administração & dosagem , Ferro/análise , Cinética , Fígado/química , Linfócitos/fisiologia , Camundongos , Camundongos Endogâmicos C57BLRESUMO
This study examined the presence of a persistent state of low-grade inflammation in sickle cell anemia patients by measuring circulating sHLA-I heterodimers and C-reactive protein during the steady state and after recent crises. Thirty-nine pediatric sickle hemoglobinopathy patients were studied during the steady state and 11 patients were evaluated within 1 month of a painful crisis. A disease severity score was generated for each patient, and soluble HLA-I (sHLA-I) and C-reactive protein levels were determined. Soluble HLA-I was significantly elevated in 55% of the steady-state group and in 36% of the recent-crisis group. The percentage of patients with elevated sHLA-I differed in the various disease subgroups in the steady state: 46% of Hb SS patients, 70% of Hb SC patients, 75% of Hb S beta-thal patients, and 20% of Hb SSF patients. Steady-state and recent-crisis sHLA-I levels were not significantly different. C-reactive protein levels were elevated in 11% of steady-state patients and in 9% of recent-crisis patients. Soluble HLA-I levels did not correlate with C-reactive protein levels or disease severity score, age, hemoglobin, reticulocyte count, platelet count, or white cell count. These results show that the majority of sickle hemoglobinopathy patients have elevated sHLA-I levels during the steady state and after recent crisis, suggesting the presence of chronic inflammation during the steady state.
Assuntos
Anemia Falciforme/sangue , Antígenos de Histocompatibilidade Classe I/sangue , Anemia Falciforme/imunologia , Proteína C-Reativa/análise , Criança , Feminino , Humanos , Masculino , Índice de Gravidade de DoençaRESUMO
Poland's syndrome, a rare congenital disorder with pectoralis muscular girdle defect, have been reported in association with lymphoreticular malignancies in the past. Childhood solid tumors in association with this congenital anomaly have not been reported so far. We describe this rare association of Poland's syndrome and Wilms tumor. Due to the possibility of increased risk of leukemogenesis in patients with Poland's syndrome, chemo-radiation therapy of Wilms tumor in our patient may increase the risk of secondary leukemia. Therapeutic modification of primary cancer in these patients may be necessary with careful long-term follow-up for early detection and treatment of secondary cancer.
Assuntos
Neoplasias Renais/complicações , Síndrome de Poland/complicações , Tumor de Wilms/complicações , Humanos , Lactente , MasculinoRESUMO
A case of 10-year-old girl with an unusual association of sickle cell disease (SCD) with systemic lupus erythematosus (SLE) is presented. The report discusses the clues to the diagnosis of this rare combination with review of relevant literature and highlights the diagnostic dilemma that may arise because of the similarity of symptoms.
Assuntos
Anemia Falciforme/complicações , Lúpus Eritematoso Sistêmico/complicações , Anemia Falciforme/diagnóstico , Criança , Diagnóstico Diferencial , Feminino , Humanos , Lúpus Eritematoso Sistêmico/diagnósticoRESUMO
Tumor necrosis factor alpha (TNF-alpha) is known to induce wasting in humans and animals. This study was undertaken to determine TNF-alpha concentrations in children with sickle cell disease (SCD) and whether high TNF-alpha levels are more likely to be present in children with growth deficits, infection, or pain crisis. Tumor necrosis factor alpha was measured using enzyme immunoassay in 143 blood samples obtained from 101 children. Mean TNF-alpha levels were higher in patients (50 pg/mL) than in 21 control children (19 pg/mL) and in 26 laboratory employees (20 pg/mL). During the follow-up period, 35%, 38%, and 28% of children with SCD had infection, pain crisis, or a blood transfusion, respectively. Mean TNF-alpha concentrations were higher in children who had an infection than in those who did not. No significant effect of pain crisis or blood transfusion was observed. Tumor necrosis factor alpha concentrations were above normal (> 40 pg/mL) in 15% of controls, 34% of children with SCD, and 52% of children with SCD who had an infection and 33% of those who did not. A higher percentage of children who had elevated TNF-alpha levels had weight (46% versus 31%) or height (50% versus 28.6%) deficits than children who had normal TNF-alpha levels. These results indicate that most children with SCD in stable condition have normal TNF-alpha concentrations and that those with high TNF-alpha levels are more likely to have growth deficits.
Assuntos
Traço Falciforme/sangue , Fator de Necrose Tumoral alfa/análise , Adolescente , Criança , Pré-Escolar , Transtornos do Crescimento/sangue , Transtornos do Crescimento/complicações , Humanos , Técnicas Imunoenzimáticas , Lactente , Traço Falciforme/complicaçõesRESUMO
Clinical laboratory evaluation of congenital hemoglobin disorders requires both the accurate identification of major and minor hemoglobin variants, and precise quantitation of these variants over a wide range of concentrations. Capillary isoelectric focusing is an automated, microanalytical technique that produces diagnostic information comparable to that obtained from multiple conventional assays now used by most hospital laboratories. This report describes the advantages of capillary isoelectric focusing for the routine primary assessment of hemoglobinopathies and thalassemias. The use of capillary isoelectric focusing for the identification of unusual hemoglobinopathies, including an extremely rare doubly heterozygous disorder (hemoglobin C/E disease), is described. Application of the technique for rapid (< 4 minutes) neonatal hemoglobinopathy screening, and for the analysis of Hb A1c to monitor glycemic control in diabetic subjects is also discussed. In an increasingly competitive and cost-conscious clinical diagnostic market, capillary isoelectric focusing is a rapid, specific, precise, and low-cost method for comprehensive primary analysis of hemoglobin variants.